Ekaterina Shevchenko

Ekaterina Shevchenko

Auto-generated profile, based on publicly available information

Ekaterina Shevchenko

Faculty of Sciences, Institute of Pharmaceutical Sciences, Department of Pharmaceutical/Medicinal Chemistry, University of Tübingen, Auf der Morgenstelle 8, Tübingen, Germany, 72076

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
FWFlorian Wittlinger
Florian Wittlinger
BOBlessing C. Ogboo
Blessing C. Ogboo
ESEkaterina Shevchenko
Ekaterina Shevchenko
TDTahereh Damghani
Tahereh Damghani
CPCalvin D. Pham
Calvin D. Pham
DHDavid E. Heppner
David E. Heppner
Bivalent molecules consisting of groups connected through bridging linkers often exhibit strong target binding and unique biological effects. However, developing bivalent inhibitors with the desired activity is challenging due to the dual motif architecture of these molecules and the variability that can be introduced through differing linker structures and geometries. We report a set of alternatively linked bivalent EGFR inhibitors that simultaneously occupy the ATP substrate and allosteric pockets. Crystal structures show that initial and redesigned linkers bridging a trisubstituted imidazole ATP-site inhibitor and dibenzodiazepinone allosteric-site inhibitor proved successful in spanning these sites. The re-engineered linker yielded a compound that exhibited significantly higher potency (~60 pM) against the drug-resistant EGFR L858R/T790M and L858R/T790M/C797S, which was superadditive as compared with the parent molecules. The enhanced potency is attributed to factors stemming from the linker connection to the allosteric-site group and informs strategies to engineer linkers in bivalent agent design.

12 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSStephan Spahn
Stephan Spahn
FKFabian Kleinhenz
Fabian Kleinhenz
ESEkaterina Shevchenko
Ekaterina Shevchenko
ASAaron Stahl
Aaron Stahl
YRYvonne Rasen
Yvonne Rasen
MBMichael Bitzer
Michael Bitzer
Fibroblast growth factor receptor (FGFR)−2 can be inhibited by FGFR-selective or non-selective tyrosine kinase inhibitors (TKIs). Selective TKIs are approved for cholangiocarcinoma (CCA) with FGFR2 fusions; however, their application is limited by a characteristic pattern of adverse events or evocation of kinase domain mutations. A comprehensive characterization of a patient cohort treated with the non-selective TKI lenvatinib reveals promising efficacy in FGFR2-driven CCA. In a bed-to-bench approach, we investigate FGFR2 fusion proteins bearing critical tumor-relevant point mutations. These mutations confer growth advantage of tumor cells and increased resistance to selective TKIs but remain intriguingly sensitive to lenvatinib. In line with clinical observations, in-silico analyses reveal a more favorable interaction pattern of lenvatinib with FGFR2, including an increased flexibility and ligand efficacy, compared to FGFR-selective TKIs. Finally, the treatment of a patient with progressive disease and a newly developed kinase mutation during therapy with a selective inhibitor results in a striking response to lenvatinib. Our in vitro, in silico, and clinical data suggest that lenvatinib is a promising treatment option for FGFR2-driven CCA, especially when insurmountable adverse reactions of selective TKIs or acquired kinase mutations occur.

30 April 2026 in ChemRxiv
Verified
Preprint
Open access
XLXiaojun Julia Liang
Xiaojun Julia Liang
CAClaudia Albertini
Claudia Albertini
TKThales Kronenberger
Thales Kronenberger
ESEkaterina Shevchenko
Ekaterina Shevchenko
ARAlexander Rasch
Alexander Rasch
Matthias GehringerMatthias Gehringer
Matthias Gehringer
The Tyrosine Kinase Expressed in Hepatocellular Carcinoma (TEC) family comprises five nonreceptor tyrosine kinases – BTK, ITK, BMX, TXK, and TEC – which play key roles in immunological signal transduction. Although BTK and ITK have been extensively studied, selective inhibitor development for TEC, TXK, and BMX remains scarce. In a recent study, we identified a new class of covalent BMX inhibitors with a 7-azaindole core. These compounds exhibit potent inhibitory activity and robust cellular target engagement but had limited selectivity across TEC family members, especially BTK, which is the closest relative of BMX. Here, we describe the next generation of BMX inhibitors that incorporate diverse N-acylamino substituents at the azaindole 5-position or variations in the linker and warhead region. These modifications were designed to exploit subtle structural differences between BMX and BTK in the pocket behind the gatekeeper residue as well as in the front pocket. Our compounds display excellent BMX potency in the sub-nanomolar range along with improved selectivity against BTK and other TEC family kinases. We identified compound 11i as a new BMX lead compound with strong cellular target engagement, good in vitro metabolic stability, a favourable kinome profile, and fast covalent inactivation kinetics. These properties position compound 11i among the best BMX chemical probes currently available.

13 September 2023 in Research Square
Verified
Preprint
Open access
PDF file
DHDavid Heppner
David Heppner
FWFlorian Wittlinger
Florian Wittlinger
BOBlessing Ogboo
Blessing Ogboo
ESEkaterina Shevchenko
Ekaterina Shevchenko
TDTahereh Damghani
Tahereh Damghani
SLStefan Laufer
Stefan Laufer
Bivalent molecules consisting of groups connected through bridging linkers often exhibit strong target binding and unique biological effects. However, developing bivalent inhibitors with the desired activity is challenging due to the dual motif architecture of these molecules and the variability that can be introduced through differing linker structures and geometries. We report a set of alternatively linked bivalent EGFR inhibitors that simultaneously occupy the ATP substrate and allosteric pockets. Crystal structures show that initial and redesigned linkers bridging a trisubstituted imidazole ATP-site inhibitor and dibenzodiazepinone allosteric-site inhibitor proved successful in spanning these sites. The re-engineered linker yielded a compound that exhibited significantly higher potency (~60 pM) against the drug-resistant EGFR L858R/T790M and L858R/T790M/C797S, which was superadditive as compared with the parent molecules. The enhanced potency is attributed to factors stemming from the linker connection to the allosteric-site group and informs strategies to engineer linkers in bivalent agent design.

25 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MRMarcel Rak
Marcel Rak
AMAmelie Menge
Amelie Menge
RTRoberta Tesch
Roberta Tesch
LBLena Marie Berger
Lena Marie Berger
DBDimitrios Balourdas
Dimitrios Balourdas
SKStefan Knapp
Stefan Knapp
Mammalian STE20-like (MST) kinases 1-4 play key roles in regulating the Hippo and autophagy pathways, and their dysregulation has been implicated in cancer development. In contrast to the well-studied MST1/2, the roles of MST3/4 are less clear, in part due to the lack of potent and selective MST3/4 inhibitors. Here, we re-evaluated literature compounds, and used structure-guided design to optimize the p21-activated kinase (PAK) inhibitor G-5555 ( 8 ) to selectively target MST3/4. These efforts resulted in the development of MR24 ( 24 ) and MR30 ( 27 ) with good kinome-wide selectivity, high potency for MST3/4, and selectivity towards the closely related MST1/2. In combination with the MST1/2 inhibitor PF-06447475 ( 2 ) the two MST3/4 inhibitors can be used to elucidate the multiple roles of MST kinases in cells. We found that MST3/4-selective inhibition caused a cell cycle arrest in the G1 phase, while MST1/2 inhibition resulted in accumulation of cells in the G2/M phase. These data point to distinct functions of these closely related kinases, which can now be addressed with subfamily-selective chemical tool compounds.

19 June 2026 in ChemRxiv
Verified
Preprint
Open access
XLXiaojun Julia Liang
Xiaojun Julia Liang
CAClaudia Albertini
Claudia Albertini
TKThales Kronenberger
Thales Kronenberger
ESEkaterina Shevchenko
Ekaterina Shevchenko
ARAlexander Rasch
Alexander Rasch
Matthias GehringerMatthias Gehringer
Matthias Gehringer
The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family comprises five non-receptor tyrosine kinases – BTK, ITK, BMX, TXK, and TEC – with key roles in immune signalling. Although BTK and ITK have been extensively studied, selective inhibitors for TEC, TXK, and BMX remain scarce. Recently, we identified 7-azaindole-based covalent BMX inhibitors with potent inhibitory activity and robust cellular target engagement but limited selectivity across TEC family members, especially BTK. Here, we describe a new generation of BMX inhibitors designed to exploit subtle structural differences between BMX and BTK by incorporating diverse N-acylamino substituents at the azaindole 5-position or variations at the linker and warhead. Our compounds display subnanomolar BMX potency and improved selectivity over BTK and other TEC kinases. Key compound 11i showed strong cellular target engagement, good in vitro metabolic stability, a favourable kinome profile, and rapid covalent inactivation kinetics, positioning it among the best BMX chemical probes currently available.